Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.55 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.55 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.55 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 7/20 | 0.96 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365632 | 0.98 | PNMT (1.00) | PNMTDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL351435 | 0.98 | PNMT (1.00) | PNMTDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL30015379 | 0.93 | DRD2 (0.96) | PNMTDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL4224148 | 0.93 | DRD2 (0.96) | PNMTDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL29580085 | 0.91 | DRD2 (1.00) | PNMTDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL1638541 | 0.91 | DRD2 (1.00) | PNMTDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL29642113 | 0.89 | PNMT (0.77) | PNMTDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL21753256 | 0.89 | PNMT (0.76) | PNMTDRD2DRD3 | |
| SCHEMBL24265588 | 0.87 | PNMT (0.80) | PNMTDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL4033305 | 0.86 | PNMT (0.79) | PNMTDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358961-B2 | Anti-HCMV compositions and methods | EVRYS BIO, LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220135556-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-107438435-B | anti-HCMV compositions and methods | 埃弗里斯生物有限责任公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-3218373-B1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200140429-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2020-05-07 | — | — | US | disclosed |
| US-10556894-B2 | Anti-HCMV compositions and methods | EVRYS BIO, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20180291016-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC | 2018-10-11 | — | — | US | disclosed |
| EP-3218373-A2 | ANTI-HCMV COMPOSITIONS AND METHODS | Forge Life Science, LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009001128-A1 | 1,2-CYCL0HEXANE DICARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005108367-A1 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | ENVIVO PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358961-B2 | Anti-HCMV compositions and methods | RPL35, RPL7, RPL5 | DRD2 4805/4885DRD3 4658/4885ADRA2A 4655/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | DRD2 3950/4885DRD3 4073/4885ADRA2A 2840/4885 |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | DRD2 3964/4885DRD3 3682/4885ADRA2A 4703/4885 |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DRD2 4600/4885DRD3 4503/4885ADRA2A 2131/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DRD2 4842/4885DRD3 4839/4885ADRA2A 3378/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | DRD2 4450/4885DRD3 4544/4885ADRA2A 2160/4885 |
| US-10556894-B2 | Anti-HCMV compositions and methods | RPL35, RPL7, RPL5 | DRD2 4805/4885DRD3 4658/4885ADRA2A 4655/4885 |
| US-20200140429-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | DRD2 4805/4885DRD3 4658/4885ADRA2A 4655/4885 |
| US-20180291016-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | DRD2 4805/4885DRD3 4658/4885ADRA2A 4655/4885 |
| US-20220135556-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | DRD2 4805/4885DRD3 4658/4885ADRA2A 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.